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Introduction: Low back pain (LBP) is ranked as one of the most prevalent health conditions. It is likely that some inflammatory
mediators could be associated with pain and disability in these patients. Photobiomodulation therapy (PBMT) is a non-
pharmacological therapy often used in patients with LBP and one of the possible mechanisms of action of therapy is modulate
inflammatory mediators. However, to date there are no studies that evaluated the effects of PBMT on the levels of inflammatory
mediators in patients with LBP. The aim of this study is to evaluate the acute effects of PBMT on systemic levels of inflammatory
mediators and pain intensity in patients with chronic non-specific low back pain.
Methods and analysis: This is a prospectively registered, two-arm randomized placebo-controlled trial with blinded patients,
assessors and therapists. Eighteen patients with chronic non-specific LBP will be randomized into 2 groups: placebo or active
PBMT. The treatment will be provided in a single session. The primary outcome will be levels of prostaglandin E2 (PGE2). The
secondary outcomes will be levels of necrosis factor alpha (TNF-a), interleukin 6 (IL-6) and pain intensity. Biochemical and clinical
outcomes will be measured at baseline and 15 minutes after the single treatment session.
Discussion:Despite PBMT be used in musculoskeletal disorders such as LBP, to the best of our knowledge this is the first study
that will investigate a possible biological mechanism behind the positive clinical effects of PBMT on non-specific chronic low back
pain.
Ethics and dissemination: The study was approved by the Regional Research Ethics Committee. The results will be
disseminated through publication in peer-reviewed international journal and conferences.
Trial registration number: NCT03859505.
Abbreviations: ELISA = enzyme-linked immunosorbent assay, IL = interleukin, LASER = light amplification by stimulated
emission of radiation, LBP = low back pain, LED = light-emitting diodes, PBMT = photobiomodulation therapy, PGE2 =
prostaglandin E2, TNF-a = necrosis factor alpha.
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Non-specific low back pain is a complex and extremely frequent
condition[1] strongly associated with high levels of disability.[2]
Some aspects can be associated with low back pain, and the
identification of these aspects is helpful in both prevention and
management of this condition.[3] One of these aspects is the
possible association between inflammatory mediators and low
back pain, since the increased of pro inflammatory cytokines
levels is often observed in painful conditions.[4,5]
Evidences have demonstrated increase of pro inflammatory
cytokines levels in patients with low back pain. Wang et al[6]
demonstrated increase of plasmatic levels of necrosis factor alpha
(TNF-a) in patients with chronic low back pain when compared
to healthy individuals, for example. However, no significant
correlation of TNF-a levels to pain intensity or disability were
identified. Moreover, it was observed that there is an increase of
TNF-a [7,8] and interleukin (IL) 6 levels in patients with acute low
back pain.[8] Thus, the presence of some inflammatory mediators
might be associated with pain and disability in patients with low
back pain, since pro inflammatory cytokines such as IL-6, TNF-a
and IL-1 contribute to the activation of nociceptors that generate
potential of action and pain hyper sensibility.[4,5]
Several nonpharmacologic and noninvasive management
options are available for patients with low back pain (e.g.,
exercises, electrophysical agents andmanual therapy).[9]However,
the mechanisms of action of available therapies to reduce pain and
disability in these patients still remain uncertain. According to the
abovementioned studies,[6–8] the modulation of inflammatory
mediators levels could be considered a possible strategy in the low
back pain management and thus, the use of photobiomodulation
therapy (PBMT) could be interesting in this case.
PBMT is a non-pharmacological and non-thermal intervention
that consists in applying a non-ionized form of light, which
includes LASER (light amplification by stimulated emission of
radiation) and LED (light-emitting diodes) from visible to infrared
spectrum.[10] PBMT is often used in the treatment of musculoskel-
etal disorders such as low back pain;[11,12] however, the exact
mechanism of action through PBMT decreases pain intensity and
disability in these patients is still unknown. Evidences suggest that
PBMT is effective in modulate inflammatory mediators such as
TNF-a, IL-1b, IL-6, IL-10 and prostaglandin E2 (PGE2), both in
experimental and clinical studies,[13–18] contributing to pain
relief[18,19] and tissue repair.[20,21] The biological responses of
PBMT on these inflammatory mediators may be targeted as
possible mechanism of action for its beneficial clinical effects.
However, currently there are no studies about the effects of
PBMT on inflammatory mediators in patients with non-specific
low back pain, investigating whether this could be a possible
mechanism of action. Therefore, the aim of this study is to
evaluate the acute effects of PBMT on systemic levels of
inflammatory mediators (TNF-a, IL-6 and PGE2) and pain
intensity in patients with chronic non-specific low back pain.2. Methods and analysis
2.1. Design
A two-arm, parallel randomized, triple-blinded (patients,
therapists and outcome assessors), placebo-controlled trial will
be performed. The protocol of this study has been prospectively
registered on Clinicaltrials.gov (NCT03859505). The study will
be conducted at Department of Global PublicHealth and Primary
Care, University of Bergen, Norway.2
2.2. Ethical aspects
The present study will follow the ethical guidelines and was
approved by the Regional Research Ethics Committee (Protocol
No. 2018/1361/REK nord). Patients will be informed about all
study procedures and asked to sign the Informed Consent Form
prior to their enrollment in the study. Research personnel will
take all appropriate and customary steps to ensure that data
remain secure and that patient privacy and confidentiality will be
maintained.2.3. Characterization of sample
Since no studies assessing the effects of PBMT on inflammatory
mediators in patients with non-specific low back pain are
available, the number of patients per group in the present study
was calculated based on a pilot study. This pilot study was
recently conducted by our research group with 3 patients per
group in order to estimate the sample size. A b value of 20% and
an a of 5%were used to calculate the sample size. The pilot study
showed that applying PBMT in patients with non-specific low
back pain resulted in levels of PGE2 (primary outcome of the
present study) of 1.05pg/ml (0.42 standard deviation), whereas
applying the placebo in patients with non-specific low back pain
resulted in levels of PGE2 of 1.52pg/ml (0.39 standard deviation).
We used the Researcher’s Toolkit to calculate the sample size
(https://www.dssresearch.com/resources/calculators/sample-size-
calculator-average). Based on the aforementioned parameters
used to calculate the sample, we found a sample of 9 patients per
group, for a total of 18 patients. Since the phototherapy device
used in the study causes no harmful thermal effects,[22] patients of
different skin colors will be recruited. The patients will be
recruited through primary care doctors and physiotherapists.2.4. Eligibility criteria
Inclusion criteria: Patients with chronic non-specific low back pain (pain or
discomfort between the costal margins and inferior gluteal
folds with or without referred pain to the lower limbs);
Persistent low back pain for at least 3 months;[23]
 Pain intensity of at least 3 points, measured by Pain Numerical
Rating Scale;[24]
Aged between 18 and 65 years;
 Both genders.
Exclusion criteria:
 Patients with severe skin diseases (e.g., skin cancer, erysipelas,
severe eczema, severe dermatitis, severe psoriasis and severe
hives lupus);
Patients with low back pain associated with nerve root
compromise (measured by clinical examination of derma-
tomes, myotomes and reflexes);[25,26]
Serious spinal pathologies such as fractures, tumors, inflam-
matory and infectious diseases;
Serious cardiovascular or metabolic disorders;
 Previous spinal surgery;
 Pregnancy.2.5. Procedures
The patients will be welcomed by the study’s blinded assessor
who will determine whether they will be eligible to participate in
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sociodemographic data and clinical history. Next, the primary
and secondary outcomes of the study will be collected and all
eligible patients will be randomized and allocated into 2
interventions groups: active PBMT or placebo PBMT. Fifteen
minutes after the end of the single treatment session, the primary
and secondary outcomes of the study will be collected again. The
Consolidated Standards of Reporting Trials flowchart summa-
rizing experimental procedures and patients is shown in Figure 1.
2.6. Randomization and blinding procedures
Prior to the single treatment session, patients will be randomized
into their respective intervention groups: placebo or active
PBMT. The randomization will be generated by a computer
program (Excel Office 2010) and performed by a participating
researcher not involved with the recruitment or evaluation of
patients. This same researcher will be responsible for program-
ming the PBMT device according to the result of the
randomization (active or placebo mode) and will be instructed
not to disclose the programmed intervention to the therapist, any
of the patients or other researchers involved in the study until its
completion. Concealed allocation will be achieved through the
use of sequentially numbered, sealed and opaque envelopes. To
ensure blinding for therapists and patients, the device will emit
the same sounds and the same information on the displayFigure 1. CONSO
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regardless of the programmed mode. Thus, patient and therapist
will be blinded throughout the treatment.2.7. Interventions
Patients will undergo the treatment (active PBMT or placebo),
according to prior randomization, in a single session:1.RTActive PBMT: The PBMT will be performed using the Multi
Radiance Medical Super Pulsed Laser MR4 console (Solon,
OH), with the SE25 (emitter with an area of 4cm2) and
LaserShower (emitter with an area of 20cm2) cluster probes as
emitters. Nine sites will be irradiated on the patient’s lumbar
region: 3 central sites on top of the spinous processes (between
T11 and T12, L2 and L3, L5 and S1), using the SE25; in the
same direction, but laterally, 3 sites on the left and 3 on the
right (on the paravertebral muscles), using the LaserShower
(LS). PBMT irradiation sites and parameters were chosen
based on a previous study.[27] The treatment will be performed
in a single session and the patients will receive a total dose of
220.05J. Table 1 shows PBMT parameters.
Placebo PBMT: Placebo PBMT will be delivered using the2.
same device and the irradiated sites will be the same that active
PBMT, but without any emission of therapeutic dose. Patients
will receive a total dose of 0J in placebo mode. The treatment








Wavelength (nm) 905 (±1) 905 (±1)
Frequency (Hz) 3000 1000
Peak power (W) - each 25 12.5
Average mean optical output (mW) - each 7.5 1.25
Dose (J) - each 1.35 0.225
Spot size of laser (cm2) - each 0.44 0.44
Number of red LEDs 4 Red 4 Red
Wavelength of red LEDs (nm) 640 (±10) 640 (±10)
Frequency (Hz) 2 2
Average optical output (mW) - each 15 15
Dose (J) - each 2.7 2.7
Spot size of red LED (cm2) - each 0.9 0.9
Number of infrared LEDs 4 Infrared 4 Infrared
Wavelength of infrared LEDs (nm) 875 (±10) 875 (±10)
Frequency (Hz) 16 16
Average optical output (mW) - each 17.5 17.5
Dose (J) - each 3.15 3.15
Spot Size of LED (cm2) - each 0.9 0.9
Irradiation time per site (sec) 180 180
Total dose per site (J) 24.75 24.30
Aperture of device (cm2) 4 20
Application mode Skin contact Skin contact
PBMT=photobiomodulation therapy.
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The primary outcome (levels of PGE2) and secondary outcomes
(levels of TNF-a and IL-6 and pain intensity) of the study will be
obtained at baseline and 15 minutes after the single treatment
session by an assessor who will not be aware of patients’
allocation to their treatment groups: Levels of TNF-a, IL-6 and PGE2 (inflammatory mediators):
measured by enzyme-linked immunosorbent assay (ELISA)
method. Blood samples (10ml) will be collected by a qualified
nurse (blinded to group allocation) and will be obtained from
the antecubital vein. One hour after collection, each sample will
be centrifuged at 3000rpm for 20minutes. Pipettes will be used
to transfer the serum to Eppendorf tubes, which will be stored
at80°C until analysis. The levels of TNF-a, IL-6 and PGE2 in
the blood samples will be determined by ELISA, using a
commercial kit and following the manufacturer’s instructions
(BD Biosciences, USA). Spectrophotometric readings will be
performed in a SpectraMax Plus 384 Absorbance Plate Reader
(Sunnyvale, CA) with 450-nm wavelength and correction to
570nm. The results of TNF-a and IL-6 will be expressed in pg/
ml and the results of PGE2 will be expressed in pg/ml.
Pain intensity: measured by the Pain Numerical Rating
Scale.[24] Pain Numerical Rating Scale evaluates pain intensity
levels perceived by the patient on an 11-point scale ranging
from 0 to 10, with 0 being ‘no pain’ and 10 ‘the worst possible
pain.[24] Patients will be instructed to score the level of pain
intensity based at the time of evaluation.
2.9. Statistical analysis
The statistical analysis will be conducted following the principles
of intention-to-treat analysis.[28] The findings will be tested for4
their normality using the Shapiro-Wilk test. Parametric data will
be expressed as mean and standard deviation and non-parametric
data as median and respective upper and lower limits. Parametric
data will be analyzed by two-way repeated measures analysis of
variance (ANOVA, time vs experimental group) with post-hoc
Bonferroni correction. Non-parametric data will be analyzed
using the Friedman test and, secondarily, the Wilcoxon signed-
rank test.2.10. Data availability
The datasets generated and analyzed during the current study will
be available from the corresponding author on reasonable
request.3. Discussion
Despite PBMT be used in musculoskeletal disorders such as low
back pain, to the best of our knowledge this is the first study that
will investigate a possible biological mechanism behind the
positive clinical effects of PBMTon non-specific chronic low back
pain. We strongly believe that this investigation can be helpful in
the management of this condition.
Non-specific low back pain is a complex health condition and
several treatment options may be used for symptoms relief.[29]
Over the years, it has been believed that some subgroups of this
population can benefit from specific treatments, responding
favorably to specific therapies.[30,31] In this way, knowing the
mechanism of action of available therapies becomes an important
aspect in this process.
PBMT triggers positive effects acting in different ways,
including increase of microcirculation,[32] cytochrome c oxidase
modulation and ATP synthesis,[33] besides modulating some
inflammatory biomarkers.[17,18] Thus, if PBMT is able to
modulate inflammatory mediators in non-specific low back pain,
patients with increased levels of these mediators might be
more responsive and consequently benefit more with the use of
therapy.
It is important to highlight that the present study is innovative
and present high methodological quality (i.e., is a randomized
controlled trial, triple blinded and prospectively registered). The
sample size was calculated to provide the appropriate statistical
power to detect precise differences for the primary outcomes of
the study; however, the sample size has not powered enough to be
correlated with the secondary outcome (pain intensity). One of
the limitations of the study is that although the PBMT parameters
were based on previous studies, there was no optimization and
only one dose will be tested.3.1. Dissemination policy
The study will be disseminated through publication in peer-
reviewed international journal and conferences.Author contributions
SST, LOPC, ECPLJ and JMB contributed to the concept and
design of the study, established the hypothesis and wrote the
original proposal. SST, LOPC, JJ, MBS, IFN, ECPLJ and JMB
contributed significantly in creating the manuscript. ECPLJ and
JMB performed critical revisions of the manuscript. SST wrote
the final version of the manuscript. All authors read and
approved the final version of the manuscript.
injury induced by trauma in rats: low-level laser therapy, diclofenac, or
Tomazoni et al. Medicine (2019) 98:15 www.md-journal.comConceptualization: Shaiane Silva Tomazoni, Leonardo Oliveira
Pena Costa, Jon Joensen,Martin Bjørn Stausholm, Ingvill Fjell
Naterstad, Ernesto Cesar Pinto Leal-Junior, Jan Magnus
Bjordal.
Funding acquisition: Shaiane Silva Tomazoni.
Investigation: Ernesto Cesar Pinto Leal-Junior.
Methodology: Shaiane Silva Tomazoni, Jon Joensen, Martin
Bjørn Stausholm, Ingvill Fjell Naterstad, Ernesto Cesar Pinto
Leal-Junior.
Project administration: Shaiane Silva Tomazoni, Jon Joensen.
Supervision: Leonardo Oliveira Pena Costa, JanMagnus Bjordal.
Writing – original draft: Shaiane Silva Tomazoni, Leonardo
Oliveira Pena Costa, Ernesto Cesar Pinto Leal-Junior, Jan
Magnus Bjordal.
Writing – review & editing: Shaiane Silva Tomazoni, Leonardo
Oliveira Pena Costa, Ernesto Cesar Pinto Leal-Junior, Jan
Magnus Bjordal.
References
[1] Hartvigsen J, Hancock MJ, Kongsted A, et al. Lancet Low Back Pain
Series Working GroupWhat low back pain is and why we need to pay
attention. Lancet 2018;391:2356–67.
[2] TulderMV. Chapter 1. European guidelines. Eur Spine J 2006;15:134–5.
[3] De Queiroz BZ, Pereira DS, Lopes RA, et al. Association Between the
Plasma Levels of Mediators of Inflammation With Pain and Disability in
the Elderly With Acute Low Back Pain: Data From the Back Complaints
in the Elders (BACE)-Brazil Study. Spine (Phila Pa 1976) 2016;41:197–
203.
[4] Cui JG, Holmin S, Mathiesen T, et al. Possible role of inflammatory
mediators in tactile hypersensitivity in rat models of mononeuropathy.
Pain 2000;88:239–48.
[5] Queiroz BZ, Pereira DS, Rosa NM, et al. Functional performance and
plasma cytokine levels in elderly womenwith andwithout low back pain.
J Back Musculoskelet Rehabil 2015;28:343–9.
[6] Wang H, Schiltenwolf M, BuchnerM. The role of TNF-Alpha in patients
with chronic low back pain-a prospective comparative longitudinal
study. Clin J Pain 2008;24:273–8.
[7] Kraychete DC, Sakata RK, Issy AM, et al. Serum cytokine levels in
patients with chronic low back pain due to herniated disc: analytical
cross-sectional study. Sao Paulo Med J 2010;128:259–62.
[8] Hasselhorn HM, Theorell T, Vingård E. Musculoskeletal Intervention
Center (MUSIC)-Norrtälje Study GroupEndocrine and immunologic
parameters indicative of 6-month prognosis after the onset of low back
pain or neck/shoulder pain. Spine (Phila Pa 1976) 2001;26:E24–9.
[9] Chou R, Deyo R, Friedly J, et al. Nonpharmacologic therapies for low
back pain: a systematic review for an american college of physicians
clinical practice guideline. Ann Intern Med 2017;166:493–505.
[10] Leal-Junior ECP, Lopes-Martins RÁB, Bjordal JM. Clinical and scientific
recommendations for the use of photobiomodulation therapy in exercise
performance enhancement and post-exercise recovery: current evidence
and future directions. Braz J Phys Ther 2019;23:71–5.
[11] Soriano F, Rios R. Gallium arsenide laser treatment of chronic low back
pain: a prospective, randomized and double blind study. Laser Ther
1998;10:175–80.
[12] Tantawy SA, Abdelbasset WK, Kamel DM, et al. Laser photo-
biomodulation is more effective than ultrasound therapy in patients
with chronic nonspecific low back pain: a comparative study. LasersMed
Sci 2018;[Epub ahead of print].
[13] De Almeida P, Lopes-Martins RÁ, Tomazoni SS, et al. Low-level laser
therapy and sodium diclofenac in acute inflammatory response induced
by skeletal muscle trauma: effects in muscle morphology and mRNA
gene expression of inflammatory markers. Photochem Photobiol
2013;89:501–7.
[14] De Almeida P, Tomazoni SS, Frigo L, et al. What is the best treatment to
decrease pro-inflammatory cytokine release in acute skeletal muscle5
cryotherapy? Lasers Med Sci 2014;29:653–8.
[15] Tomazoni SS, Leal-Junior EC, Pallotta RC, et al. Effects of photo-
biomodulation therapy, pharmacological therapy, and physical exercise
as single and/or combined treatment on the inflammatory response
induced by experimental osteoarthritis. Lasers Med Sci 2017;32:101–8.
[16] Tomazoni SS, Frigo L, Dos Reis Ferreira TC, et al. Effects of
photobiomodulation therapy and topical non-steroidal anti-inflamma-
tory drug on skeletal muscle injury induced by contusion in rats-part 2:
biochemical aspects. Lasers Med Sci 2017;32:1879–87.
[17] Aver Vanin A, De Marchi T, Tomazoni SS, et al. Pre-exercise infrared
low-level laser therapy (810 nm) in skeletal muscle performance and
postexercise recovery in humans, what is the optimal dose? A
randomized, double-blind, placebo-controlled clinical trial. Photomed
Laser Surg 2016;34:473–82.
[18] Bjordal JM, Lopes-Martins RAB, Iversen VV. A randomised, placebo
controlled trial of low level laser therapy for activated Achilles tendinitis
with microdialysis measurement of peritendinous prostaglandin E2. Br J
Sports Med 2006;40:76–80.
[19] Chow RT, Johnson MI, Lopes-Martins RA, et al. Efficacy of low-level
laser therapy in the management of neck pain: a systematic review and
meta-analysis of randomised placebo or active-treatment controlled
trials. Lancet 2009;374:1897–908.
[20] Tomazoni SS, Frigo L, Dos Reis Ferreira TC, et al. Effects of
photobiomodulation therapy and topical non-steroidal anti-inflamma-
tory drug on skeletal muscle injury induced by contusion in rats-part 1:
morphological and functional aspects. Lasers Med Sci 2017;32:
2111–20.
[21] Tomazoni SS, Leal-Junior EC, Frigo L, et al. Isolated and combined
effects of photobiomodulation therapy, topical nonsteroidal anti-
inflammatory drugs, and physical activity in the treatment of osteoar-
thritis induced by papain. J Biomed Opt 2016;21:108001.
[22] Grandinétti Vdos S, Miranda EF, Johnson DS, et al. The thermal impact
of phototherapy with concurrent super-pulsed lasers and red and
infrared LEDs on human skin. Lasers Med Sci 2015;30:1575–81.
[23] AiraksinenO, Brox JI, Cedraschi C, et al. Chapter 4. European guidelines
for the management of chronic nonspecific low back pain. Eur Spine J
2006;15:s192–300.
[24] Costa LO, Maher CG, Latimer J, et al. Clinimetric testing of three self-
report outcome measures for low back pain patients in Brazil: which one
is the best? Spine (Phila Pa 1976) 2008;33:2459–63.
[25] Magee DJ. Orthopedic physical assessment. 6Alberta, Canada: Elsevier;
2008. 569–618.
[26] Delitto A, George SZ, Van Dillen L, et al. Low Back Pain. Clinical
practice guidelines linked to the international classification of function-
ing, disability, and health from the orthopaedic section of the American
Physical Therapy Association. J Orthop Sports Phys Ther 2012;42:
A1–57.
[27] Tomazoni SS, Costa LDCM, Guimarães LS, et al. Effects of photo-
biomodulation therapy in patients with chronic non-specific low back
pain: protocol for a randomised placebo-controlled trial. BMJ Open
2017;7:e017202.
[28] Elkins MR, Moseley AM. Intention-to-treat analysis. J Physiother
2015;61:165–7.
[29] Maher C, Underwood M, Buchbinder R. Non-specific low back pain.
Lancet 2017;389:736–47.
[30] Hicks GE, Fritz JM, Delitto A, et al. Preliminary development of a clinical
prediction rule for determining which patients with low back pain will
respond to a stabilization exercise program. Arch Phys Med Rehabil
2005;86:1753–62.
[31] Childs JD, Fritz JM, Flynn TW, et al. A clinical prediction rule to identify
patients with low back pain most likely to benefit from spinal
manipulation: a validation study. Ann Intern Med 2004;141:920–8.
[32] Tullberg M, Alstergren PJ, Ernberg MM. Effects of low-power laser
exposure on masseter muscle pain and microcirculation. Pain
2003;105:89–96.
[33] Albuquerque-Pontes GM, Vieira RP, Tomazoni SS, et al. Effect of pre-
irradiationwith different doses, wavelengths, and application intervals of
low-level laser therapy on cytochrome c oxidase activity in intact skeletal
muscle of rats. Lasers Med Sci 2015;30:59–66.
